Correction: The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine (Oncotarget (2015) 6 (4992–5004) DOI: 10.18632/oncotarget.3214)

Deok Beom Jung; Miyong Yun; Eun Ok Kim; Jaekwang Kim; Bonglee Kim; Ji Hoon Jung; Enfeng Wang; Debabrata Mukhopadhyay; Edward Hammond; Keith Dredge; Viji Shridhar; Sung Hoon Kim

doi:10.18632/oncotarget.27216

Correction: The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine (Oncotarget (2015) 6 (4992–5004) DOI: 10.18632/oncotarget.3214)

Deok Beom Jung, Miyong Yun, Eun Ok Kim, Jaekwang Kim, Bonglee Kim, Ji Hoon Jung, Enfeng Wang, Debabrata Mukhopadhyay, Edward Hammond, Keith Dredge, Viji Shridhar, Sung Hoon Kim

Research output: Contribution to journal › Comment/debate

1 Citation (Scopus)

Abstract

The IHC pictures of ‘Control #1 group’ and ‘PG545 #2 group’ have been removed from Figure 6. In addition, the ‘Cyclin D1 in Control 1 group’ is mistakenly similar to the IHC picture of ‘PCNA in Gem group’ already presented in Figure 5F. The corrected Figure 6 is shown below. The authors declare that these corrections do not change the results or conclusions of this paper. (Figure presented.)

Original language	English
Pages (from-to)	5669
Number of pages	1
Journal	Oncotarget
Volume	10
Issue number	54
DOIs	https://doi.org/10.18632/oncotarget.27216
Publication status	Published - 1 Sept 2019

Bibliographical note

Publisher Copyright:
Jung et al.

Access to Document

10.18632/oncotarget.27216

Fingerprint

Dive into the research topics of 'Correction: The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine (Oncotarget (2015) 6 (4992–5004) DOI: 10.18632/oncotarget.3214)'. Together they form a unique fingerprint.

Cite this

Jung, D. B., Yun, M., Kim, E. O., Kim, J., Kim, B., Jung, J. H., Wang, E., Mukhopadhyay, D., Hammond, E., Dredge, K., Shridhar, V., & Kim, S. H. (2019). Correction: The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine (Oncotarget (2015) 6 (4992–5004) DOI: 10.18632/oncotarget.3214). Oncotarget, 10(54), 5669. https://doi.org/10.18632/oncotarget.27216

@article{b7f5e69d2a49437885d9e0712810c871,

title = "Correction: The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine (Oncotarget (2015) 6 (4992–5004) DOI: 10.18632/oncotarget.3214)",

abstract = "The IHC pictures of {\textquoteleft}Control #1 group{\textquoteright} and {\textquoteleft}PG545 #2 group{\textquoteright} have been removed from Figure 6. In addition, the {\textquoteleft}Cyclin D1 in Control 1 group{\textquoteright} is mistakenly similar to the IHC picture of {\textquoteleft}PCNA in Gem group{\textquoteright} already presented in Figure 5F. The corrected Figure 6 is shown below. The authors declare that these corrections do not change the results or conclusions of this paper. (Figure presented.)",

author = "Jung, {Deok Beom} and Miyong Yun and Kim, {Eun Ok} and Jaekwang Kim and Bonglee Kim and Jung, {Ji Hoon} and Enfeng Wang and Debabrata Mukhopadhyay and Edward Hammond and Keith Dredge and Viji Shridhar and Kim, {Sung Hoon}",

note = "Publisher Copyright: Jung et al.",

year = "2019",

month = sep,

day = "1",

doi = "10.18632/oncotarget.27216",

language = "English",

volume = "10",

pages = "5669",

journal = "Oncotarget",

issn = "1949-2553",

publisher = "Impact Journals LLC",

number = "54",

}

Jung, DB, Yun, M, Kim, EO, Kim, J, Kim, B , Jung, JH, Wang, E, Mukhopadhyay, D, Hammond, E, Dredge, K, Shridhar, V & Kim, SH 2019, 'Correction: The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine (Oncotarget (2015) 6 (4992–5004) DOI: 10.18632/oncotarget.3214)', Oncotarget, vol. 10, no. 54, pp. 5669. https://doi.org/10.18632/oncotarget.27216

Correction: The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine (Oncotarget (2015) 6 (4992–5004) DOI: 10.18632/oncotarget.3214). / Jung, Deok Beom; Yun, Miyong; Kim, Eun Ok et al.
In: Oncotarget, Vol. 10, No. 54, 01.09.2019, p. 5669.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Correction

T2 - The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine (Oncotarget (2015) 6 (4992–5004) DOI: 10.18632/oncotarget.3214)

AU - Jung, Deok Beom

AU - Yun, Miyong

AU - Kim, Eun Ok

AU - Kim, Jaekwang

AU - Kim, Bonglee

AU - Jung, Ji Hoon

AU - Wang, Enfeng

AU - Mukhopadhyay, Debabrata

AU - Hammond, Edward

AU - Dredge, Keith

AU - Shridhar, Viji

AU - Kim, Sung Hoon

N1 - Publisher Copyright: Jung et al.

PY - 2019/9/1

Y1 - 2019/9/1

N2 - The IHC pictures of ‘Control #1 group’ and ‘PG545 #2 group’ have been removed from Figure 6. In addition, the ‘Cyclin D1 in Control 1 group’ is mistakenly similar to the IHC picture of ‘PCNA in Gem group’ already presented in Figure 5F. The corrected Figure 6 is shown below. The authors declare that these corrections do not change the results or conclusions of this paper. (Figure presented.)

AB - The IHC pictures of ‘Control #1 group’ and ‘PG545 #2 group’ have been removed from Figure 6. In addition, the ‘Cyclin D1 in Control 1 group’ is mistakenly similar to the IHC picture of ‘PCNA in Gem group’ already presented in Figure 5F. The corrected Figure 6 is shown below. The authors declare that these corrections do not change the results or conclusions of this paper. (Figure presented.)

UR - http://www.scopus.com/inward/record.url?scp=85072710058&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.27216

DO - 10.18632/oncotarget.27216

M3 - Comment/debate

C2 - 31608142

AN - SCOPUS:85072710058

SN - 1949-2553

VL - 10

SP - 5669

JO - Oncotarget

JF - Oncotarget

IS - 54

ER -

Jung DB, Yun M, Kim EO, Kim J, Kim B , Jung JH et al. Correction: The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine (Oncotarget (2015) 6 (4992–5004) DOI: 10.18632/oncotarget.3214). Oncotarget. 2019 Sept 1;10(54):5669. doi: 10.18632/oncotarget.27216

Correction: The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine (Oncotarget (2015) 6 (4992–5004) DOI: 10.18632/oncotarget.3214)

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this